FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FB-102 overview
Forte Biosciences overview
Forte Biosciences is a biopharmaceutical company that develops and commercializes product candidates for the treatment of skin. The company offers lead product candidate such as FB-102. FB-102 is used for the for the treatment of autoimmune diseases such as Vitiligo and Alopecia Areata (AA). Alopecia Areata nonscarring hair loss generally on the scalp but can also other areas of the body. Vitiligo is an autoimmune disease in which the immune system attack melanocytes?. Its services include clinical trials. The company has operations across the US. Forte Biosciences is headquartered in Torrance, California, the US.
For a complete picture of FB-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.